Julius Strauss, M.D.
Dr. Strauss is the Director of the Clinical Trials Group of the Laboratory of Tumor Immunology and Biology. His clinical research is focused on the use of novel agents capable of inducing the immune system to recognize and kill cancer cells. Dr. Strauss is very interested in the use of these agents in combination with each other as well as "standard" cytotoxic therapies in an effort to improve their efficacy. Dr. Strauss also has an interest in using these therapies to help patients with the fewest treatment options, including patients with rare diseases.
Phase I Trial Using aMulti-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in Patients with Advanced CancerOpen - Not yet Recruiting Protocol Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-18-C-0032Investigator Julius Strauss, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Alanvin Orpia, BSN, R.N. 240-760-7972
A Randomized Phase II trial of Standard of Care Alone or in Combination with Ad-CEA vaccine and Avelumab in Patients with Previously Untreated Metastatic Colorectal CancerOpen - RecruitingNCI Protocol ID NCI-17-C-0057Investigator Julius Strauss, M.D.
As Director of the Clinical Trials Group of the Laboratory of Tumor Immunology and Biology (LTIB), Dr. Strauss's clinical research is focused on the use of novel agents capable of inducing the immune system to recognize and kill cancer cells. Dr. Strauss focuses on the use of these agents in combination as well as “standard” cytotoxic therapies in an effort to improve their efficacy. Ongoing trials include the use of vaccines, immunocytokines and single or dual functioning checkpoint inhibitors (e.g. anti-PD-L1 +/- TGFbeta TRAP) either as monotherapies or in combination with each other or with cytotoxic therapies (chemotherapy, radiation). Dr. Strauss's trials enroll patients with multiple tumor types with a focus on gastrointestinal, genitourinary, gynecologic, and head and neck malignancies. Dr. Strauss also has an interest in using these therapies to help patients with the fewest treatment options, including patients with rare diseases.
Dr. Strauss has been involved in the following areas of clinical investigation: (a) In collaboration with the LTIB's CRADA partner, the laboratory is characterizing a tumor-targeting immunocytokine. NHS-IL12 is a fully human monoclonal antibody (MAb) that binds DNA/histone in necrotic tumor, which is fused to human IL-12 heterodimers. The agent was designed to reduce the toxicity of rec. IL-12 protein while maintaining its immune-enhancing properties at the tumor site. We have shown that the immunocytokine has anti-tumor activity in a range of tumor models and is extremely effective when used in combination therapies in several models. We have recently completed a first-in-human clinical trial with NHS-IL12 and are currently evaluating this cytokine in combination with anti-PD-L1 therapy. (b) The laboratory is characterizing, in collaboration with our CRADA partner, an anti-PDL1 Mab (avelumab) as well as a bifunctional fusion MAb combining an anti-PD-L1 and a TGFbeta TRAP (M7824). Unlike other anti-PD-L1 MAbs, these agents are capable of mediating antibody-dependent cell-mediated cytotoxicity (ADCC) of human carcinomas cells. We have completed a first-in-human clinical trial with avelumab, which is currently being evaluated in multiple phase III tumor specific trials and was recently FDA approved for a rare skin malignancy known as Merkel Cell carcinoma. We have also completed a first-in-human clinical trial of M7824, which is currently being evaluated in phase 1b trials in multiple tumor specific expansion cohorts. (c) In collaboration with our CRADA partners, we have initiated or plan to initiate soon first-in-human trials evaluating multiple different therapeutic cancer vaccine platforms including CV301 (rV-, rF-CEA-MUC1-TRICOM), MVA-brachyury-TRICOM, fowlpox-brachyury-TRICOM, Ad5[E1-, E2b-]-CEA, Ad5[E1-, E2b-]-MUC1, Ad5[E1-, E2b-]-brachyury, and Ad5[E1-, E2b-]-PSA.
Selected Key Publications
- Expert Opin Biol Ther. 16: 895-901, 2016. [ Journal Article ]
- Expert Rev Vaccines. 15: 907-14, 2016. [ Journal Article ]
- Lancet Oncol. 16: 1013-5, 2015. [ Journal Article ]
- Curr Oncol Rep. 17: 45, 2015. [ Journal Article ]
Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand.Expert Rev Anticancer Ther. 14: 1243-9, 2014.
Dr. Strauss received his M.D. from Stony Brook University Medical Center School of Medicine in 2010 and completed his internal medicine residency at Montefiore Medical Center in 2013. He joined the NCI Medical Oncology Service as a Medical Oncology Fellow in 2013. Dr. Strauss is Director of the Clinical Trials Group of the Laboratory of Tumor Immunology and Biology, NCI. He also has an adjunct appointment in the Genitourinary Malignancies Branch. He is board certified in medical oncology and internal medicine. Dr. Strauss is part of the larger effort of the Laboratory of Tumor Immunology and Biology to create new immunotherapies for the treatment of cancer. Dr. Strauss’s areas of expertise: immunotherapy; therapeutic cancer vaccines; immune checkpoint inhibitors
|Andrea Burmeister PA-C||Physician's Assistant (Contr)|
|Bonnie L. Casey||Writer-Editor|
|Margaret Gatti-Mays M.D.||Staff Clinician|
|Cynthia Moye||Patient Care Coordinator (Contr)|
|Camilo Pacheco Puentes||Patient Care Coordinator (Contr)|